Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
1.770
-0.085 (-4.58%)
At close: Oct 2, 2026, 4:00 PM EDT
1.758
-0.012 (-0.69%)
After-hours: Oct 2, 2026, 7:50 PM EDT
Decoy Therapeutics Revenue
Decoy Therapeutics had revenue of $227.63K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $227.63K.
Revenue (ttm)
$227.63K
Revenue Growth
n/a
P/S Ratio
5.09
Revenue / Employee
$20,694
Employees
11
Market Cap
1.16M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 1.84M | -3.39M | -64.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 27.82M |
| Curis | 4.31M |
| Scinai Immunotherapeutics | 1.49M |
| Endovia Health Sciences | 32.09K |
| Virax Biolabs Group | 12.42K |
DCOY News
- 4 days ago - Decoy Therapeutics to Present at The Small Cap Showcase - GlobeNewsWire
- 5 days ago - Decoy Therapeutics’ human coronaviruses candidate shows positive PK data - TheFly
- 5 days ago - Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program - PRNewsWire
- 11 days ago - Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release - PRNewsWire
- 11 days ago - Why Is Penny Stock Decoy Therapeutics (DCOY) Up 48% Today? - TipRanks
- 11 days ago - Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules - PRNewsWire
- 12 days ago - Decoy Therapeutics to explore pan-filovirus program via FDA Animal Rule pathway - TheFly
- 12 days ago - Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding - PRNewsWire